Ceftolozane + tazobactam (Zerbaxa)

Class: Drug combination: beta-lactam (cephalosporin, fourth generation) + beta-lactamase inhibitor (penicillanic acid sulfone)

Spectrum of activity:	Gram-negative
Details of activity:	Approved for: complicated urinary tract infections, complicated intra-abdominal infections, acute pyelonephritis (kidney infection); other potential indications: hospital-acquired bacterial pneumonia/ ventilator-associated pneumonia
Combined with other compounds:	Yes
Institute where first reported:	Cubist Pharmaceuticals; Merck & Co; Astellas Pharma
Year first mentioned:	2012
Highest developmental phase:	Approved by FDA in 2014
Development status:	Approved

Chemical structure(s):
Canonical SMILES:	CC(C)(C(=O)O)O/N=C(\C1=NSC(=N1)N)/C(=O)N[C@@H]2C(=O)N3C(=C(C[N+]4=CC(=C(N)N4C)NC(=O)NCCN)CS[C@H]23)C(=O)[O-].C[C@]1(CN2C=CN=N2)[C@H](C(=O)O)N3C(=O)CC3S1(=O)=O
Isomeric SMILES:	C[C@@]1([C@@H](N2C(S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3.CC(C)(C(=O)O)O/N=C(\C1=NSC(=N1)N)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)[O-]
InChI:	InChI=1S/C23H30N12O8S2.C10H12N4O5S/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24;1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42);2-3,7-8H,4-5H2,1H3,(H,16,17)/b31-11+;/t12-,18-;7?,8-,10-/m10/s1
InChI Key:	GRHWKSLBMDQBQW-KZVOOCJBSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/86291594

External links:
Guide to Pharmacology:	ceftolozane
Citations:	http://aac.asm.org/content/56/6/3086.long http://aac.asm.org/content/57/12/6305.full http://aac.asm.org/content/57/6/2809.full